Podcasts about biotech

In this episode of Careers in Discovery, we're joined by Paulo Fontoura, Chief Medical Officer at Xaira Therapeutics. Paulo shares his journey from neurology and academia into big pharma and now Biotech, reflecting on what he learns along the way. He talks about Xaira's bold mission to use AI not just to speed up drug development, but to rethink how we do it entirely - overcoming human limitations in how we explore biology. We also discuss why he leaves a successful career in pharma for the high-risk world of startups, how he stays optimistic in the face of failure, and what it really takes to build a company that's aiming to change the game. A thoughtful conversation with a leader bringing deep experience - and fresh perspective - to the future of drug discovery.

Bitcoin; Bonds; Tariffs; Ukraine; Asylum; Biotech & China | Yaron Brook Show

Dr. Anne Marie Morse walks into the studio like a one-woman Jersey Broadway show and leaves behind the best damn TED Talk you've never heard. She's a neurologist, sleep medicine doc, narcolepsy expert, founder of D.A.M.M. Good Sleep, and full-time myth buster in a white coat. We talk about why sleep isn't a luxury, why your mattress does matter, and how melatonin is the new Flintstones vitamin with a marketing budget. We unpack the BS around sleep hygiene, blow up the medical gaslighting around “disorders,” and dig into how a former aspiring butterfly became one of the loudest voices for patient-centered science. Also: naps, kids, burnout, CPAPs, co-sleeping, airport pods, the DeLorean, and Carl Sagan. If you think you're getting by on five hours of sleep and vibes, you're not. This episode will make you want to take a nap—and then call your doctor.RELATED LINKSdammgoodsleep.com: https://www.dammgoodsleep.comLinkedIn: https://www.linkedin.com/in/anne-marie-morse-753b2821/Instagram: https://www.instagram.com/dammgoodsleepDocWire News Author Page: https://www.docwirenews.com/author/anne-marie-morseSleep Review Interview: https://sleepreviewmag.com/practice-management/marketing/word-of-mouth/sleep-advocacy-anne-marie-morse/Geisinger Bio: https://providers.geisinger.org/provider/anne-marie-morse/756868SWHR Profile: https://swhr.org/team/anne-marie-morse-do-faasm/FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

For this exciting conversation, I am joined by NanoPalm CEO and co-founder Dr. Ali Alhasan and by Charles River Executive Director Ramin Baghirzade, who joins us to talk about Charles River's incubator program for startups like NanoPalm. Alhasan and his co-founder, Dr. Samar Alsudir, began NanoPalm to help reach rare disease patients who could benefit from advanced gene therapies. NanoPalm is the first company to conduct a gene therapy clinical trial in Saudi Arabia, with plans for many more treatments in the works. Listen now to learn about the trial, Charles River's incubator program, and about the current state of biotech startup in Saudi Arabia.

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Merger-Monday bei Ansys & Synopsys. Waters & Becton. Vielleicht auch bei Kenvue und Kraft Heinz. Nicht mehr bei Autodesk und PTC. Sonst gibt's Zölle, Zuckerberg hat Milliarden, Zalando hat TikTok-Shop-Konkurrenz und Bitcoin feiert Krypto-Woche. China und Biotech ist in 2025 eine sehr geile Kombo. Wer profitiert und wie können wir profitieren? Es geht um WuXi AppTec (WKN: A2PAMX), BeOne Medicines (WKN: A41ANK), Hansoh Pharma (WKN: A2PLRC), 3SBIO (WKN: A14T7Q). Diesen Podcast vom 15.07.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

We love to hear from our listeners. Send us a message. On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, how he spun his academic discoveries out into a biotech company developing new obesity drugs, the need for obesity treatments with fewer side effects than currently available GLP-1 therapies, and the value of pairing scientific leadership with a strong business partner as CEO. This episode of the Business of Biotech is brought to you by Ecolab. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Show Notes: Pete Zorn, a lawyer and biotech executive, spent nine years in North Carolina, attending law school at the University of Carolina, Chapel Hill. He moved back to the Boston area with his wife and child where he stayed with his law firm, working remotely before taking an in-house position with one of his clients. He took the company public and stayed there for 11 years. He has since worked with three other biotech companies in various business and legal capacities, and is currently the president and Chief Legal Officer of Genevant. The Leading Nucleic Acid Delivery Company in the World Genevant specializes in lipid nanoparticles, which help protect and deliver nucleic acids like mRNA in the body to do its job. The company partners with biotech and pharma companies worldwide. Pete explains that nucleic acids, which store and express genetic material, can address diseases by encoding for a gene or addressing gene deficiencies, defects, or overexpression. However, nucleic acids can degrade in the body if not properly protected, making lipid nanoparticles an emerging mode of delivering nucleic acids. He talks about the concept of a lipid nanoparticle, which is a small fat bubble that encapsulates or envelops nucleic acid, protecting it from enzymes in the body and directing it to the desired tissue or cell type. If not protected, nucleic acids like mRNAs would be degraded in the body before they can have their intended effect. Genevant is a pioneer of lipid nanoparticles and owns a substantial amount of intellectual property in the space. They manufacture only at a research scale, but they license the technology to companies, who will manufacture the products in their plants using Genevant's technology. Partnership Deals in Biotech Pete explains that, unlike mergers and acquisition deals where negotiation is mostly about price, in life science collaborations you negotiate everything, including sharing intellectual property and responsibility, how parties will work together, and, of course, price.  It's an ongoing relationship that is being negotiated. The most challenging part is negotiating the deal if the partnership comes to an end. This is to ensure that the parties are in the right place when the collaboration ends. Pete discusses the various aspects of a biotech partnership, including ongoing intellectual property (IP) development, responsibility, allocation, and governance issues. He mentions two main categories: consideration of licensing and payment for technology, and the allocation of intellectual property. Genevant's Technology Platform Genevant, a company that expands its technology platform through these deals, owns improvements to their platform. Special arrangements may be included for those that require the payload or partner's technology. These details are crucial in negotiating and time management. In addition to licensing and payment, partnering arrangements involve governance, confidentiality representations, commitments, and risk allocation. The agreed amounts can change depending on external factors and must be carefully negotiated. Joining the Biotech World Pete discusses his career in biotech, highlighting the advantages of being with a smaller, growing company compared to working with a larger, established company. He shares his first deal with a big pharma company in his 20s, where he had to negotiate a complex deal for a company that desperately needed to make the deal happen. He talks about the challenges involved, including the human challenge of establishing trust. The company needed to define the rights they were giving to another company while retaining enough space to allow them to work with other companies as well. The technical challenge was to draw fine lines in the constantly evolving scientific area, while also allowing them room to work independently. The deal was a nine-month negotiation and a 300-page contract, but it was a seminal moment for his company, which has since merged out of existence. Drug Development Success Pete talks about drug development and successes achieved. He shares a story of a company that had a successful phase two, which led to collaboration with a big pharma company. However, the company subsequently endured a disastrous phase three, which resulted in a dramatic downturn in stock price for the company. Despite this, the company was not sued, which he takes pride in. He emphasizes the importance of taking risks in drug development, as it allows the company to succeed and advance. He approaches the legal side of his job by finding ways to accomplish business objectives while managing that risk. Career Turning Points Pete also shares some turning points in his career. He continues to do deal making and is currently involved in intellectual property litigation related to lipid nanoparticles used in COVID vaccines. The conversation turns to the world of chief legal officers in biotech companies, specifically in the Boston area. Pete shares his experience working remotely for a North Carolina company and then with a European company, which allowed him to build networks and interact with other professionals. He also shares his life outside of work, raising two children – including a son with autism – and focusing on their well-being. He emphasizes that autism is a spectrum, with no two kids being the same. He mentions that there are different challenges for parents of children with autism and offers a few words of advice to parents in that situation. Influential Harvard Professors and Courses Pete, who was a psychology major at Harvard, mentions his favorite class was a civil rights class with the knowledgeable, charismatic and powerful speaker, Julian Bond. He mentions how he took a year off before going to Law school, and how happenstance played a role in his career in the life sciences industry.  Timestamps: 03:48: Pete Zorn's Role at Genevant and Nucleic Acid Delivery  08:13: Complex Partnerships in Biotech  14:59: Pete Zorn's Entry into Biotech and Key Deals  22:11: Challenges and Successes in Biotech  27:14: Pete Zorn's Career and Personal Life  29:06: Advice for Parents of Children with Autism 37:07: Reflections on Harvard  Links: Website: https://www.genevant.com/ LinkedIn: https://www.linkedin.com/in/pete-zorn-8b63391/   Featured Non-profit: The featured non-profit of this week's episode is the Children's Hospital of Los Angeles  recommended by Cara Familian Natterson who reports: “ Hi. This is Cara Familian Natterson, class of 1992. The featured nonprofit of this episode of The 92 Report is Children's Hospital Los Angeles, also known as CHLA. I joined the CHLA Board of Directors last year, but I've been working with the doctors at this amazing hospital for decades. CHLA isn't just one of the top 10 children's hospitals in the country, it's also the only one that is a safety net hospital with more than 70% of their patients on medicaid. They will never turn a child away, regardless of a family's financial situation or immigration status. If you want to learn more, go to C, H, L, A, dot, O, R, G, and now here is Will Bachman with this week's episode.” To learn more about their work, visit: CHLA.org.

Diane King Hall moderates a special Market Overtime episode with two respected Wall Street Minds. Jay Woods joins Diane at the NYSE set to preview this week's big bank earnings and explains why he's "very bullish" on the financials group. Later, Gareth Soloway dives into the technical levels to watch in some of the biggest names around, including Nvidia (NVDA) and GE Vernova (GEV). 0:00-0:45 Introduction - Taped on Friday July 111:10-1:47 Woods: Word of the Year "Uncertainty"1:48-2:25 Breaking Down Delta's Earnings2:26-3:06 Why Company Guidance Needs to Be Watched3:07-4:34 Health of Overall Airlines Group4:35-6:45 Big Banks Outlook6:46-7:15 Why Jay's Bullish on Banks, IPO Market7:16-7:49 Tariff Impact on Earnings7:50-9:05 Crypto Adoption Outlook, Jamie Dimon's Commentary9:06-9:52 Watching for M&A in Financials Sector9:53-11:30 Increased Tariffs, Increased Uncertainty?11:31-13:15 Biotech & Pharma Stocks, Watching Patent Expiration14:00-15:20 Introduction Gareth Soloway, Market Rally Since April15:21-18:00 What SPX Chart Shows18:01-19:00 Earnings Season Outlook19:01-21:00 Charting Nvidia21:01-24:20 Taiwan Semiconductor's Technicals24:21-25:43 GE Vernova's "Measured Move" 25:44-27:02 "Soup-er" Chart: Campbell's27:03-28:02 Why Gareth's Watching China Market28:03-28:48 Gareth on Small Caps, IWM======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA has rejected Capricor's therapy for Duchenne Muscular Dystrophy (DMD), causing shares to plunge due to insufficient evidence of effectiveness for cardiomyopathy associated with DMD. Lilly and Sarepta also received Complete Response Letters (CRLs) for their therapies. Moderna has won full approval for its COVID-19 vaccine for higher-risk kids, while Pacira has cut staff in San Diego. The FDA has released a cache of CRLs, providing insights into the journeys to market for various drugs. AbbVie has acquired Ichnos Glenmark's lead myeloma antibody, and Ultragenyx's stock plummeted after a late-stage trial disappointment. Kennedy postponed a preventive care panel meeting after a Supreme Court win. Transitioning from one piece of news to the next, let's move on to the webinar exploring digitization strategies for drug development. Stay tuned for more updates in the pharmaceutical industry.

Dr. Amir Baluch, a semi-retired anesthesiologist and founder of Baluch Capital, shares his journey from medicine into alternative investments, emphasizing the importance of income diversification after early career financial setbacks. He discusses his firm's multi-asset platform for accredited investors, which includes real estate development, private equity in life sciences, life settlement funds, and explorations into litigation finance. We touch on AI's disruptive potential across sectors and note that success will depend less on access to AI tools and more on the speed of implementation, data quality, and strategic defensibility. We discuss...  Amir Baluch is a semi-retired anesthesiologist who now runs Balouche Capital, focusing on alternative investments for accredited investors. Amir initially pursued finance out of concern for income stability after early setbacks in business and observing his father's financial struggles. Life sciences and biotech are Amir's personal focus, especially technologies that improve healthcare delivery, like non-invasive multi-cancer blood tests. Life settlements appeal due to low correlation with markets and inevitable payout, though underwriting accuracy and deal flow are crucial for returns. Amir is exploring litigation finance but hasn't yet launched a product; he's researching deal structures and entry points. Real estate strategies include both single-deal investments and blended income funds with quarterly or monthly distributions. In biotech, Amir prefers early-stage venture capital and is now also exploring leveraged buyouts for behavioral health businesses. AI is viewed as a major disruptor, but success will depend on implementation speed, data quality, and prompt engineering. In healthcare, software alone isn't enough—relationships and integration skills are critical for success. Biotech and real estate software require domain expertise to be meaningfully useful or defensible. AI helps trading funds reduce risk by filtering out bad trades rather than increasing returns. Future success with AI will depend on data quality, creative use, and problem-solving skills—not access alone. Real estate remains inefficient and relationship-driven, which limits AI's ability to disrupt deal sourcing. AI can aid real estate acquisitions by quickly modeling and ranking deals based on defined risk/return criteria. Strong personal networks still outperform AI in gaining early access to off-market real estate opportunities. Today's Panelists: Kirk Chisholm | Innovative Wealth Diana Perkins | Trading With Diana Follow on Facebook: https://www.facebook.com/moneytreepodcast Follow LinkedIn: https://www.linkedin.com/showcase/money-tree-investing-podcast Follow on Twitter/X: https://x.com/MTIPodcast For more information, visit the show notes at https://moneytreepodcast.com/from-medicine-to-alternative-investments-dr-amir-baluch-728 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Hella Kohlhof, CSO at Immunic. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hella, covering: How the 'waste of two molecules' led to the spin-out creation of Immunic Therapeutics. The perfect blend of a founding team willing to split responsibility, learn and have a go. Ending up as a Nasdaq-listed company via a reverse merger... and all the new challenges that came with it. Immunic's divide-and-conquer global outsourcing strategy, while retaining tight control. Examples of how geopolitical issues have impacted a biotech's growth. Hella leads the Immunic's scientific strategy, including mode of action research, preclinical studies, and biomarker development. Dr. Kohlhof brings deep expertise in immunology, oncology, and drug development, with previous roles at 4SC AG, where she led preclinical and clinical projects. She holds a doctorate in biology from Ludwig Maximilians University of Munich and completed her postdoc at the Helmholtz Centre, focusing on B cell development. She holds several patents, has co-authored numerous publications, and is a regular speaker at scientific and industry events. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Data in Biotech, Jesse Paquette, co-founder and Chief Science Officer of Tag.bio, joins Ross Katz to explore how data mesh architecture and FAIR data principles are transforming clinical and research workflows in life sciences. From harmonizing legacy systems to enabling AI-readiness, Jesse shares how Tag.bio empowers domain experts to make data-driven decisions faster and more effectively. ​​What You'll Learn in This Episode: >> How Tag.bio leverages data mesh and FAIR principles to democratize biomedical data access. >> The challenges biotech firms face with legacy infrastructure and clinical trial data. >> The importance of harmonized, version-controlled data products in AI-driven research. >> Why smaller pharma and life sciences firms benefit most from Tag.bio's agile platform. Meet Our Guest Jesse Paquette is the co-founder and Chief Science Officer of Tag.bio, where he leads scientific strategy for AI-powered analytics. With over two decades in life sciences, he specializes in building tools that help researchers interpret complex biomedical data independently. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Tag.bioConnect with Jesse Parquette on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The FDA has recently released over 200 complete response letters (CRLs) as part of its initiative to enhance transparency regarding the reasons behind the rejection of new drug and biologics applications. This effort reflects the agency's commitment to being more open with the public about its decision-making processes.In other news, AbbVie has made a significant acquisition by purchasing Ichnos Glenmark's lead myeloma antibody for nearly $2 billion, including a substantial upfront payment of $700 million. However, Ultragenyx and Mereo Biopharma faced challenges as their stocks declined following the announcement that the phase II/III study of their osteogenesis imperfecta candidate did not yield strong results during an interim analysis.Furthermore, there is growing concern surrounding the potential dismissal of the U.S. Preventive Services Task Force, following a Supreme Court ruling that affirmed Health Secretary Robert F. Kennedy Jr.'s authority to remove its members at his discretion. This development has raised questions about the future of preventive health initiatives in the country.For drug developers, finding the right balance between speed and quality is essential for achieving success in the industry. To optimize processes and leverage technology throughout the development journey, new digitization strategies are being explored. Embracing these advancements can help streamline operations and enhance overall efficiency in drug development efforts.

The female cochineal beetle may not be aware of it, but it owes a debt of gratitude to Joshua Britton. In February, Britton's Debut Biotech unveiled a breakthrough set to disrupt how beauty products are formulated. Using biotechnology, the San Diego-based company created a vegan, bio-identical alternative to a common red cosmetics colorant traditionally harvested from the cochineal beetle. This beetle pigment can be found on ingredient labels as “carmine,” “cochineal extract,” “crimson lake,” “natural red 4” or “C.I. 75470.” A quick online search reveals carmine in products from Stila, Fenty Beauty, Maybelline, M.A.C., Chanel and dozens more brands. Britton has had a team of 10 researchers working on this for around four years. Debut has invested around $10 million in the project thus far, and the new, vegan pigment will soon be available for the industry at scale. Britton has a PHD in biochemistry and organic chemistry and launched Debut six years ago. Debut is backed by L'Oréal's science-focused incubator arm Bold and was named a Time 100 2025 Most Influential Companies of the Year. The company also launched its first in-house skin-care brand, called Deinde, in 2024. Glossy awarded Britton a Glossy 50 award last year. Britton joins the Glossy Beauty Podcast to discuss the breakthrough and its impact, and provides a primer on the power of biotechnology in beauty today. But first, Lexy Lebsack is joined by senior reporter Emily Jensen to discuss the news of the week. This includes early results from Amazon Prime Days, which is on track to be the retailer's largest annual sale yet. Jensen and Lebsack also discuss Sephora's newest brand, Beauty of Joseon, which is known for its viral and hard-to-get sunscreens. Founder Sumin Lee joined the Glossy Beauty Podcast late last year to discuss its stunning growth in the U.S. market. The company hopes to sell $120 million in the U.S. market this year.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Merck recently made a significant move in the pharmaceutical industry by acquiring Verona for $10 billion, gaining access to the commercial COPD drug Ohtuvayre. This acquisition is viewed as a strategic decision to offset potential revenue loss when the patent for Keytruda expires. In other news, the Supreme Court has suspended an injunction preventing RFK Jr.'s HHS cuts. AstraZeneca also finalized a deal with JCR worth up to $825 million for gene therapy AAVs. Additionally, Trump has threatened 200% pharma tariffs, but has provided a one-year grace period for implementation. Drug developers are being advised to digitize their outsourcing path for optimal success in the industry. Furthermore, Novo Nordisk has terminated a deal with Hims & Hers, while Lilly has received an FDA label update for an Alzheimer's drug. Various developments in the longevity biotech space have also been highlighted. Stay tuned for more updates in the pharmaceutical industry.

How to Launch a Biotech Startup in 2025 | Real Talk with Richard Bendis #richardbendis #healthtech #entrepreneurshipWhat does it really take to build a successful biotech startup in today's tough investment climate? Please visit our website to get more information: https://swangroup.net/ In this episode, I sit down with Richard Bendis, the powerhouse behind BioHealth Innovation, to unpack the raw reality of starting a life sciences company in 2025. From navigating non-dilutive funding and government partnerships to leveraging EIR programs and tech transfer strategies, we dive into the entrepreneurial ecosystem that's shaping the future of biotech. Richard's insights span decades of innovation policy, investment, and commercialization strategy - exactly what founders and future founders need right now. If you're looking to launch a biotech company or you're struggling with funding, this conversation is packed with practical knowledge.Links from this episode:✅ Get to know more about Richard Bendis:  https://www.linkedin.com/in/richbendis  ✅ Learn more about BioHealth Innovation: https://www.biohealthinnovation.org

  LiquidTrust: A New Era of Cross-Border Payment Protection for Small Business w/ Saujin Yi - AZ TRT S06 EP11 (273) 6-29-2025       What We Learned This Week ·         SMBs Face Major Risk in Cross-Border Payments Small businesses are exposed to significant risk when dealing with international suppliers, lacking the same protections that consumers receive. ·         Traditional Bank Wires Are Outdated for Global SMB Transactions Bank wires, SWIFT networks, and intermediary banks remain the default but are slow, costly, and offer limited recourse if something goes wrong. ·         Digitized Escrow Can Level the Playing Field A modernized escrow system, like Liquid Trust, can serve as a trusted middle layer in transactions, enabling secure, conditional fund releases. ·         Banks Are Adopting Fintech Tools for SMB Clients Liquid Trust is expanding by partnering with banks, offering them technology to better serve small businesses with secure payment processing. ·         A Major Gap Exists for SMB Payment Protections There's a growing opportunity to provide insurance-style protections, dispute resolution, and cash flow tools for smaller, international transactions.   Guest: Saujin Yi, Founder - LiquidTrust LKIN: https://www.linkedin.com/in/saujin/ Tech entrepreneur, investor, and advisor focused on fintech, future of work, and backing women/minorities. Personal mission is to create a #newplayingfield. Saujin Yi has been talking to founders and bankers who are watching a payment crisis unfold in real time— small business owners wiring full payments to overseas suppliers, only to have their goods withheld or renegotiated because tariffs shifted mid-transaction. These aren't hypothetical's. Inventory is being held hostage, and most of these businesses have no recourse. Saujin is the founder of LiquidTrust, a fintech platform helping SMBs protect themselves. She talks about: ·  The tariff whiplash hitting cross-border supply chains ·  Why small businesses are exposed to all the payment risk ·  How new tools like LiquidTrust's Micro Escrow Pay are helping level the playing field With LiquidTrust, small businesses can wire to 175 countries with built-in counterparty verification, or opt for a holding account that only releases funds when terms are met. It's a timely conversation and offering that I think SMBs would benefit from learning about.   https://www.linkedin.com/company/liquidtrust/ https://www.liquidtrust.io/ 43% of US SMBs make global payments but 75% are unsatisfied with their current options. LiquidTrust is an innovative global pay solution tailored for the needs of small- and medium-sized businesses that also safeguards their transactions from fraud and loss. We offer 2 global payment methods: 1) Direct Pay - Fast global payments to 175 countries within 1-2 days. Safer than traditional wires, with counterparty verification for enhanced security. 2) Pay by Trust ("micro-escrows") - Escrow-like protection against fraud and loss. Offers peace of mind without complexity and high costs of traditional escrows.  Of the $6.9T US import/export payment volume, 2/3 goes unprotected because current payment protection products like letters of credit are too complex and expensive. 9 out of 10 SMB owners constantly worry about fraud and loss because non-payment or non-delivery would be devastating to business survival. We partner with banks to make our self-serve, white-label solution available to their current and potential customers and capture the $9B+ revenue opportunity and related deposits. LiquidTrust builds on the foundation established by Liquid (est. 2019), evolving to meet new opportunities.     Notes: Segment 1: Solving Cross-Border Payment Risk for SMBs In early 2025, small businesses began feeling the pressure of rising tariffs and payment complications with overseas vendors. For many SMBs, cross-border transactions are a daily reality—but the tools available to them haven't kept pace with the global nature of modern commerce. The Traditional Payment Model Historically, payments to overseas partners have relied on the banking system as the intermediary. This means: ·         Transactions typically occur via international wire transfers. ·         These wires use the SWIFT network, involving multiple intermediate banks. ·         Funds are converted between currencies, often with unpredictable fees or delays. While this may work for large enterprises, small businesses often bear more risk in these transactions, lacking sufficient tools for protection or recourse. Many SMBs today operate a “borderless” business model—based in the U.S. but with 50% or more of their partnerships overseas. The Need for Simplicity and Trust Small businesses need a solution that is: ·         Reliable for both sides of the transaction ·         Simple to use without requiring financial expertise ·         Built on trust, with built-in mechanisms to reduce risk Liquid Trust introduces a new payment model for SMBs—simplifying cross-border payments through a system built around "micro escrow."   Segment 2: Micro Escrow: Modern Protection for Small Deals Much like real estate uses escrow accounts to protect both buyers and sellers, Liquid Trust applies the same principle to small business payments. Traditionally, escrow has only been available for large deals. Liquid Trust brings this to small transactions by digitizing the process. Here's how it works: ·         A buyer can invite and verify a vendor into the platform. ·         Funds are held in escrow, not released until pre-set conditions are met. ·         A built-in dispute resolution and arbitration system ensures fairness. ·         The process is as simple as a "Buy Now, Pay Later" model. This transforms the transaction dynamics. Instead of the buyer taking on 100% of the risk with a wire or upfront deposit, both parties share risk more equitably—improving trust, satisfaction, and cash flow for SMBs. The Bigger Problem: Why Change the System? In the traditional system, there are “winners” and “losers”: ·         Winners: Vendors who receive payment up front with little risk. ·         Losers: Buyers who send money and hope everything works out. But smart SMBs realize that keeping vendors happy is also good business. Building long-term trust and smoother cash flow on both sides of a deal can elevate all partners. There's a clear gap in the market: SMBs have no access to tools like consumer credit protections, and banks often don't want to get involved in smaller payments like a $20,000 invoice. It's not profitable for them. Liquid Trust fills this gap.   Segment 3: Bank Partnerships: Scaling Trust and Access Initially, Liquid Trust served SMBs directly. But a strategic pivot is now enabling banks, attorneys, and accountants to offer Liquid Trust's technology to their small business clients. Why banks? ·         They are already trusted advisors for SMBs. ·         They need better digital tools to serve modern business clients. ·         They lack solutions for smaller, international transactions. With this new model, banks integrate Liquid Trust into their ecosystem, giving small businesses access to tools they never had before: protections, conditional payments, and streamlined digital processing. The Vision Behind Liquid Trust Liquid Trust was founded by an engineer with a background in finance and technology startups. Originally designed as an accounts payable solution, the platform pivoted after identifying massive friction and risk in global SMB payments. Key insights: ·         SMBs struggle with payment protections across borders. ·         Legal recourse is impractical—lawsuits are expensive and hard to enforce internationally. ·         Many vendors are in regions where you simply can't “go knock on the door.” Liquid Trust, now evolving under the name Escrow Pay, has raised a seed round and is expanding into: ·         Financial institutions and banks ·         Online marketplaces ·         Business-to-business platforms The future of SMB payments lies in trust, transparency, and built-in protections—all delivered through easy-to-use financial technology.     Biotech Shows: https://brt-show.libsyn.com/category/Biotech-Life+Sciences-Science   AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023   Tech Topic: https://brt-show.libsyn.com/category/Tech-Startup-VC-Cybersecurity-Energy-Science  Best of Tech: https://brt-show.libsyn.com/size/5/?search=best+of+tech   ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.  

Quang Pham went from being a 10-year-old refugee airlifted out of Vietnam to becoming a Marine pilot, and the CEO of a NASDAQ-listed biotech company. In this conversation, he shares the exact lessons that guided each transition.   Key insight: On decision-making: “As a young officer, we were taught to make decisions… there's not enough time to consult with everybody. You gotta make a decision to keep moving and then adjust along the way.” This became his foundational leadership principle across sectors. On capital discipline: “In the private sector and entrepreneurial world, resources are scarce… you have to treat it with the utmost respect and spend it wisely.” Military spending habits do not translate to startups. On performance and promotion: “You work hard, but you have to produce results.” Early in his corporate career, he assumed promotions would come automatically. They did not. On defining success: “You have to follow and pursue what makes you happy. Not what your family or your culture or society wants.” As a Vietnamese refugee, choosing the military was going against all cultural expectations. On raising capital without pedigree: “I lacked the skills to present to venture capitalists… so I spent a lot of time at Toastmasters picking up new speaking skills.” Within 90 days of leaving his corporate job, he secured venture funding as a first-time CEO. On pitch strategy: “You have to get to the key points… in the first seven or ten minutes, if not sooner.” Investors have limited attention. He focused his pitch on buyer, payment frequency, and execution, not theoretical market size. On cold outreach: “It was just three sentences. Who I was, what my company did, something about our common [background].” This approach led to two successful VC rounds. On leadership transitions: “I knew that I had the skills and the backing and that the baton had to be passed… the company flourished and I was then just a shareholder.” Founders must be willing to step aside to scale. On AI and decision-making: “There is somebody making decisions for AI, the decision to use AI, the decision to pay for AI… at the end of the day, we still need entrepreneurs and leaders.” This episode offers practical reflections for those navigating leadership transitions, capital formation, and decision-making in complex, resource-constrained settings.   Get Quang's new book here: https://quangxpham.com/   Here are some free gifts for you:   Overall Approach Used in Well-Managed Strategy Studies free download: www.firmsconsulting.com/OverallApproach   McKinsey & BCG winning resume free download: www.firmsconsulting.com/resumepdf   Enjoying this episode? Get access to sample advanced training episodes here: www.firmsconsulting.com/promo

Are you ready to pitch your biotech startup to investors but unsure what they're actually looking for? In this episode, host James Zanewicz, JD, LLM, RTTP, sits down with Travis Manasco, MD — Principal at Solas BioVentures, practicing ICU physician, and Tulane alumnus — for a clear-eyed look at what it takes to secure life science venture capital. From communicating clearly to avoiding common missteps, Travis offers practical advice that every founder should hear before stepping into a pitch meeting. In this episode, you'll discover: The "goat, moat, float, and dote" framework Solas uses to evaluate investments. What makes an investor-ready pitch — and why focus matters more than ambition. How founders can build lasting relationships with VCs and avoid first-call deal-killers. Whether you're refining your deck or just starting your fundraising journey, this episode is packed with actionable insights to move your biotech forward. Links: Connect with Travis Manasco, MD, and check out Solas BioVentures. Connect with James Zanewicz, JD, LLM, RTTP and learn about Tulane Medicine Business Development and the School of Medicine. Connect with Penelope Manasco, MD, Elizabeth Chabe, MBA, Tari Suprapto, PhD, and David Adair, MBA. Learn more about Francis Medical, I-O Urology, Vektor Medical, and OpenEvidence. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

This week on Careers in Discovery, we're joined by Tim Sparey, Executive Chair at Tay Therapeutics and Non-Executive Chair at Concr. Tim shares his journey from early days as a medicinal chemist at Merck to a career spanning business development, CEO roles, and now chairing multiple early-stage Biotech companies. He talks about the shift from operator to portfolio leader, how he evaluates new opportunities, and why capital efficiency is a critical part of Biotech success - especially in the current market. We also dive into Tay's approach to doing more with less, how Concr is applying AI to reshape precision oncology, and what Tim looks for in founding teams. Along the way, he reflects on the value of learning from setbacks, building trust with investors, and why simplicity, storytelling, and timing make all the difference.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Medical societies, including the American Academy of Pediatrics, have filed a lawsuit against RFK Jr. over changes to COVID-19 vaccine policies. They argue that his directive to remove COVID-19 from vaccination guidelines for healthy pregnant women and children puts them at risk of serious illness. Concentra has acquired struggling biotech company Cargo Therapeutics in a $200 million buyout. President Trump's tax law has restored orphan drug exemptions, cut Medicaid funding, and threatened the 340B program, while giving pharmacy benefit managers a pass. The ALS community has petitioned the FDA to reconsider Brainstorm's cell therapy Nurown, citing recent survival data. Drug developers are exploring new digitization strategies to optimize processes and embrace technology in drug development. Overall, the text discusses legal action against RFK Jr. over vaccine policy changes, recent acquisitions in the biotech industry, implications of Trump's tax law on healthcare programs, petitions regarding ALS therapies, digitization strategies in drug development.

Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Daphne Koller, CEO of insitro and cofounder of Coursera, joins Leadership Next to unpack a bold idea: Just as calculus revolutionized our understanding of physics, AI could do the same for biology. In this episode, Koller explains how insitro is blending biology and machine learning to unlock new treatments for diseases like ALS and fatty liver. She also opens up about her leap from academia to entrepreneurship, the ethical challenges of data collection, and why the future of medicine lies in personalized, AI-driven care. Plus, her take on why humans and machines must work in tandem to drive meaningful innovation. 

Treg-based cell therapies are nearing a clinical proof-of-concept inflection point, but in an environment that has dramatically shifted with the advent of CAR T therapies for autoimmune diseases. On the latest BioCentury This Week podcast, BioCentury's analysts discuss what these cell therapies need to show to be relevant in the fast-changing I&I world, and which types of indications may best suit the cells' unique profile.The team also explores the biotech sector's ongoing struggle to capture the interest of generalist investors, and what the next major theme might be to draw them back.The analysts then break down the key provisions in the recently passed U.S. reconciliation tax bill, highlighting the positive and negative developments, as well as the missed opportunities for the industry. This episode of BioCentury This Week was sponsored by IQVIA Biotech. View full story: https://www.biocentury.com/article/656376#biotech #biopharma #pharma #lifescience #CellTherapy #TregTherapy #CAR_T00:01 - Sponsor Message: IQVIA Biotech01:19 - Treg Inflection Point10:57 - Biotech's Next Big Story22:36 - Tax Bill ConsequencesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Kalvista has received approval for the first on-demand hereditary angioedema pill after facing challenges with the FDA. Meanwhile, Robert F. Kennedy Jr. has made significant cuts and rehires at the Department of Health and Human Services. Upcoming biopharma milestones to watch include developments in obesity and rare genetic diseases, as well as therapies targeting the TIGIT space. Drug developers are exploring digitization strategies to optimize processes and embrace technology in the development journey amidst a busy buyout period in the pharmaceutical industry.Transitioning to the next news, the text discusses four therapies targeting TIGIT that are still holding on in a troubled space where many others have failed. It also highlights the potential of using AI and genetics to reduce adverse drug reactions and restore public trust in the pharmaceutical industry. Additionally, it mentions the FDA's decision to remove risk evaluation and mitigation strategies for certain cell and gene therapies, as well as recent developments in ultrarare therapies, cancer treatments, and regulatory changes. The text provides information on the HHS overhaul by the numbers, including rehiring hundreds of employees but still operating with reduced staff.

President Trump announcing 25% tariffs on goods from Japan and South Korea, and a handful of other countries are also in the crosshairs. What it means for markets, as they back off record levels. Plus biotech stocks have been on the upswing since April. Can the trend continue? We talk to one top analyst to find out.Fast Money Disclaimer

We love to hear from our listeners. Send us a message. This week's episode is one from the road, recorded in front of a live audience in Boston's Seaport neighborhood during the BIO conference (special thanks to MasterControl for making it happen). Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies (aka 'Epic Bio') explains how epigenetic editing is revolutionizing genetic medicine by controlling gene expression, without cutting DNA like traditional CRISPR technologies. Amber talks about FSHD, a progressive muscular dystrophy, how the company raised $68 million in Series B funding despite challenging market conditions, her partnership with Springbok Analytics for AI analysis of MRI images, working with a CDMO to manufacture a new treatment modality, and navigating the FDA during a time of disruption. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Breakthrough in Cancer TreatmentExciting news in the world of oncology as a new breakthrough in cancer treatment has been announced. Researchers have discovered a novel therapy that targets specific mutations in cancer cells, leading to significantly improved outcomes for patients. This groundbreaking treatment is set to revolutionize the way we approach cancer care and could potentially save countless lives in the future.## FDA Approval for New DrugIn other news, the FDA has granted approval for a new drug that shows promising results in the treatment of a rare genetic disorder. This drug has undergone rigorous testing and has been shown to be both safe and effective in clinical trials. The approval of this medication represents a major milestone in the field of rare disease treatment and offers hope to patients who previously had limited options for managing their condition.## Collaboration between Pharmaceutical CompaniesA collaboration between two leading pharmaceutical companies has been announced, with the goal of developing innovative therapies for a range of diseases. This partnership brings together the unique expertise and resources of both companies, potentially leading to the discovery of new treatments that could benefit patients worldwide. This collaboration highlights the importance of working together to address unmet medical needs and advance the field of medicine.## Advancements in Gene TherapyExciting advancements have been made in the field of gene therapy, with researchers reporting promising results in early clinical trials. Gene therapy has the potential to treat a wide range of genetic disorders by replacing or modifying faulty genes. These latest developments represent a significant step forward in the field of genetic medicine and offer hope to patients who previously had limited treatment options.## ConclusionIn conclusion, these recent developments in the world of Pharma and Biotech are not only groundbreaking but also offer hope for patients facing serious medical conditions. From breakthroughs in cancer treatment to advancements in gene therapy, the future of medicine is looking brighter than ever. Stay tuned for more updates on these exciting developments as we continue to follow the latest news in Pharma and Biotech.

Today's guests are Dan Rasmussen, founder of Verdad Advisers, and D.A. Wallach, a venture capital investor for Time BioVentures and an acclaimed recording artist. Pharrell Williams discovered D.A.'s band Chester French and signed the group to Interscope Records. In today's episode, Dan & D.A. discuss the current state of biotech, the impact of AI on healthcare, and the role of innovative treatments in transforming patient care. The three also touch on the shifting narrative of private equity, tax strategies, venture capital returns, and much more. (0:00) Starts (1:02) D. A.'s journey from musician to investor (7:30) Dan on the state of biotech (19:14) Opportunities and challenges in healthcare and biotech (33:16) Private equity market dynamics (41:30) Public vs. private markets and venture capital returns analysis (59:54) Opportunities in international markets (1:09:00) Tax strategies (1:16:39) Potential biotech investments (1:19:00) Global investment trends ----- Follow Meb on X, LinkedIn and YouTube For detailed show notes, click here To learn more about our funds and follow us, subscribe to our mailing list or visit us at cambriainvestments.com ----- Follow The Idea Farm: X | LinkedIn | Instagram | TikTok ----- Interested in sponsoring the show? Email us at Feedback@TheMebFaberShow.com ----- Past guests include Ed Thorp, Richard Thaler, Jeremy Grantham, Joel Greenblatt, Campbell Harvey, Ivy Zelman, Kathryn Kaminski, Jason Calacanis, Whitney Baker, Aswath Damodaran, Howard Marks, Tom Barton, and many more.  ----- Meb's invested in some awesome startups that have passed along discounts to our listeners. Check them out here!  ----- Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Learn more about your ad choices. Visit megaphone.fm/adchoices

Karl and Erum bring on Dr. Alexander Titus, a commissioner on the National Security Commission on Emerging Biotechnology, to explore the exciting and challenging intersections of biotechnology and policy. Alexander shares his experiences from his unique journey across academia, government, and industry, diving into the role of biosecurity, the potential of synthetic biology, and the emerging convergence of tech and bio. They discuss ambitious projects like de-extincting the woolly mammoth, advances in biodefense, and the impacts of AI on biotech innovation. It's a conversation that sheds light on how cutting-edge biotech could shape the future and the necessary balance between innovation and ethical responsibility.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠Chapters:00:00:00 - Behind the Scenes of Bureaucracy00:00:30 - Democracy's Turning Point00:02:23 - A Fiery Day in Prospect Park00:04:20 - How Spaces Shape Our Health00:08:35 - Enter Alexander Titus: Biosecurity Visionary00:10:13 - Biotech: The New Face of National Defense00:15:09 - Where Tech and Policy Collide00:23:10 - The Future of Biosecurity Unfolds00:28:02 - Bold Science vs. Ethical Boundaries00:30:24 - Robotics Meets Biotech: What's Next?00:33:29 - Hard Lessons from Cross-Industry Giants00:35:49 - Innovation Clashes with Red Tape00:36:11 - The Power of Expertise in Shaping Policy00:42:26 - Biotech's Hidden Environmental Risks00:45:42 - The Commission's Bold Path Forward00:48:45 - Parting Thoughts: What Lies AheadTopics Covered: biotech, biosecurity, national security commission on emerging biotechnology, policyEpisode Links: ⁠The Wild Life of Our Bodies by Robb Dunn ⁠ ⁠Geerat Vermeij⁠ ⁠BTO - Biological Technologies Office of DARPA⁠⁠ Bioeconomy.XYZ⁠ ⁠The Nobel Turing Challenge⁠ ⁠Range by David Epstein⁠ ⁠NSCEB Interim Report⁠ ⁠AI Safety Institute⁠ ⁠The Echo Wife by Sara Gailey⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Have a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ /⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ /⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ /⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ /⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ /⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠GrowEverything website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: groweverything@messaginglab.comMusic by: NihiloreProduction by: Amplafy Media

Nick Johnston, a former biotech banker and entrepreneur, founded Alis Biosciences to solve one of the biggest challenges that every biotech might face on its road – how to maximize shareholders' value when a public-listed company loses market confidence? Alis creates a safety netfor shareholders by giving the trapped capital back and supporting the company with promising science to get back on track. Since its launch in 2025, Alis has identified over 300 small-cap biotech companies representing nearly $30 billion in underutilized capital, and has already completed successful take-private deals that delivered over 90% of uncommitted cash back to investors - faster and more efficiently than traditional liquidation processes. In this episode, you will hear about:Why Nick started Alis Biosciences, and how his background in healthcare banking shaped the model.How stagnation in capital markets leaves early-stage biotech companies in limbo and how Alis offers an innovative path forward.Why it still makes sense to invest in new science, and how Alis distinguishes between value traps and scientific opportunity.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people aged 50-59 who are at risk of severe disease, following recommendations from ACIP members he had previously fired. Biogen CEO Chris Viehbacher tried to strike a deal with Sage as the company searched for a way forward after setbacks, but Sage was not interested. In other news, late-stage stumble for Cosentyx sets Novartis back in autoimmune conditions, and Gilead eyes HIV market domination with a twice-yearly treatment. Additional stories include biotech leaders and investors urging the FDA to maintain access to Mifepristone, Regeneron scoring a nod for a bispecific drug for multiple myeloma, and the increasing demand for bioinformatics roles in the industry.

The promise of generative AI in pharma and biotech is huge, but it's also fraught with complexity, especially when it comes to integrating these systems into highly regulated environments. From monitoring evolving guidelines to balancing operational efficiency and data integrity, the journey from hype to real-world impact is filled with both opportunity and skepticism.In this episode, David Brühlmann sits down with Abhijeet Satwekar, Innovation Manager at Merck Healthcare's Global Analytical Development. Abhijeet has spent years on the front lines of digital transformation in the biotech sector, and his current mission: implementing generative AI for regulatory guideline monitoring, without giving the quality team a collective heart attack. He offers a no-nonsense roadmap for biotech leaders looking to streamline compliance, harness AI potential, and future-proof their operations.Here are three reasons you should hit play on this episode:From Proof of Concept to Real-World Implementation: Discover how Abhijeet's team moved beyond early excitement to tackle regulatory, IT, and data privacy requirements, carving a safe and compliant path for bringing generative AI tools into GxP and GMP-adjacent workflows.Human-in-the-Loop Isn't Optional: Learn why user training, prompt engineering, and close collaboration between scientists and AI are essential for extracting meaningful (and accurate) insights, especially in environments where routine and regulation reign supreme.ROI and Regulation - The Balancing Act: Hear candid perspectives on measuring the return on investment for new digital tools, addressing skeptics closer to manufacturing, and why the real game-changer might just be a community-driven, industry-wide approach to regulatory acceptance.Wondering how to unlock GenAI's full potential - or just avoid the common pitfalls? Dive into this episode for practical strategies, cautionary tales, and actionable insights from someone who's actually navigated the compliance minefield.Bring AI into your pipeline with confidence, clarity, and compliance.Connect with Abhijeet Satwekar:LinkedIn: https://www.linkedin.com/in/abhijeetsatwekarNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing development: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotechSupport the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. A judge has suspended mass layoffs at the Department of Health and Human Services, ruling that the staff cuts are likely unlawful as the agency does not have the authority to make such changes without Congress. In other news, private equity firms have recently acquired Bluebird Bio, a gene therapy biotech company, raising questions about their motivations. Additionally, RFK Jr. is advocating for changes to the vaccine injury compensation program to include COVID-19 vaccines, while the FDA is considering regulatory action on Argenx's Vyvgart Hytrulo due to safety concerns. The article also discusses Gilead's plans for dominance in the HIV market with a new drug, and other updates in the pharmaceutical industry.Private equity firms are increasingly targeting biotech companies, with Bluebird Bio recently being acquired by two firms. The first half of the year saw a surge in M&A activity in the pharmaceutical industry, with big pharmas like Eli Lilly and Novartis making multiple deals. Deals related to Alzheimer's disease also saw a significant increase following the approval of new treatments. Gilead is expanding its presence in the HIV market with a new drug, while GSK is also vying for market dominance. Other notable deals include AbbVie's acquisition of Capstan and Novartis' partnership for cardiovascular disease targets. Overall, the industry is seeing increased activity and interest from private equity firms and big pharma companies.

Today's show:It's another blockbuster panel of insiders, as Alex sits down with Astasia Myers from Felicis, Matt Turck from First Mark Capital, and D.A. Wallach of Time BioVentures. AI is reshaping early-stage investing, with startups raising record-setting rounds adn chasing $100B+ markets. Meanwhile, biotech faces a “Great Depression” as public markets stay shut, putting added pressure on private capital. In healthcare, AI-powered virtual doctors promise to bring world-class medical advice to everyone, while fertility tech could revolutionize IVF by automating embryo handling and slashing costs. Hear our VC experts exclusive thoughts on these trends and much more!Timestamps:(2:21) The post-Q2 landscape and everyone's immediate reactions(05:00) Why biotech is in a “Great Depression,” even for AI companies!(9:36) CLA - Get started with CLA's CPAs, consultants, and wealth advisors now at https://claconnect.com/tech(12:14) Overpriced vs. high-performing: Do high prices ALWAYS mean low expected returns and vice versa?(14:50) Mega markets: how AI is different from past software shifts(18:58) Everyone's companies are CRUSHING IT: why genAI has crazy tailwinds right now(20:33) Sentry - New users get 3 months free of the Business plan (covers 150k errors). Go to http://sentry.io/twist and use code TWIST(21:46) Product-market fit and revenue durability in AI(24:29) Marketing and community development for early stage founders(25:14) AI advancements in humor, avatars, and healthcare(29:30) Public - Take your investing to the next level with Public. Build a multi-asset portfolio and earn 4.1% APY on your cash—with no fees or minimums. Start now at public.com/twist.(30:45) Healthcare innovation and AI foundation models(35:37) AI differentiation, OpenAI valuation, and infrastructure companies(43:08) User experience in LLMs and AI inference costs(51:21) AI healthcare applications and founding team trends(56:28) Hiring trends, burn rates, and outsourcing in biotech(1:01:51) Government investment in biotech and the European AI ecosystem(1:06:43) Academic founders and the Felicis Fellows program(1:09:10) Recent exits and the outlook for the upcoming quarters(1:12:27) Innovations in fertility treatments and prenatal testing(1:15:51) Summary of bullish trends and future outlook(1:16:14) Closing remarks and future check-in plansSubscribe to the TWiST500 newsletter: https://ticker.thisweekinstartups.comCheck out the TWIST500: https://www.twist500.comSubscribe to This Week in Startups on Apple: https://rb.gy/v19fcpFollow Lon:X: https://x.com/lonsFollow Alex:X: https://x.com/alexLinkedIn: ⁠https://www.linkedin.com/in/alexwilhelmFollow Jason:X: https://twitter.com/JasonLinkedIn: https://www.linkedin.com/in/jasoncalacanisThank you to our partners:(9:36) CLA - Get started with CLA's CPAs, consultants, and wealth advisors now at https://claconnect.com/tech(20:33) Sentry - New users get 3 months free of the Business plan (covers 150k errors). Go to http://sentry.io/twist and use code TWIST(29:30) Public - Take your investing to the next level with Public. Build a multi-asset portfolio and earn 4.1% APY on your cash—with no fees or minimums. Start now at public.com/twistGreat TWIST interviews: Will Guidara, Eoghan McCabe, Steve Huffman, Brian Chesky, Bob Moesta, Aaron Levie, Sophia Amoruso, Reid Hoffman, Frank Slootman, Billy McFarlandCheck out Jason's suite of newsletters: https://substack.com/@calacanisFollow TWiST:Twitter: https://twitter.com/TWiStartupsYouTube: https://www.youtube.com/thisweekinInstagram: https://www.instagram.com/thisweekinstartupsTikTok: https://www.tiktok.com/@thisweekinstartupsSubstack: https://twistartups.substack.comSubscribe to the Founder University Podcast: https://www.youtube.com/@founderuniversity1916

Today we talk the end of quarter performance for quarter two of 2025. How did you do? We also cover a wide range of economic and market topics, beginning with the complexities of investing in artificial intelligence, lessons on succession planning, leadership transitions, and the importance of understanding demographic and power dynamics in both politics and investing. We note that large-cap growth, tech, and industrials led Q2 performance, while energy and real estate lagged. Mounting debt, rising delinquencies, and wage garnishment were cited as signs of economic stress, especially among younger and lower-income Americans, but the U.S. is still regarded as one of the best places to live. Today we discuss...  AI emerges as a hot investing theme, but it's difficult to get meaningful public equity exposure to the trend. We talks lessons for business owners on succession planning and the difference between operators and visionaries. You should invest in yourselves, learn how to work with AI, and become irreplaceable in the workforce. They conclude that unlike past tech revolutions, understanding AI is more about mindset, prompting skills, and creative application than simply buying stock exposure. Warren Buffett can be both the greatest investor of all time and underperform over the last 25 years. Buffett's investment challenges are partly due to managing massive capital, but he also strayed from his original strategy. Buffett should have retired decades ago and left day-to-day decisions to others. This is a parallel between aging leaders in investing and aging politicians who refuse to step down. The Baby Boomer generation is described as unintentionally draining economic resources through demographic trends. Understanding leadership transitions and generational shifts is crucial for evaluating companies and markets. Q2 market performance shows large-cap growth outperforming small-cap and value stocks. Sectors like industrials, communications, and tech led, while energy, real estate, and healthcare lagged. High beta, momentum, and pure growth factors outperformed, while high dividend and low volatility underperformed. Treasury bonds, especially international, were among the best-performing fixed income assets. Precious metals like gold, silver, and uranium led commodities; agricultural products like corn and wheat lagged. Many top-performing countries are printing money, boosting markets, despite geopolitical or structural issues. Biotech investing is highly complex due to multiple layers of science, regulation, and operational risk. Investors don't need to invest in every trendy sector—understanding is more important than participation. Crypto markets have rebounded, with Ethereum and Bitcoin showing strong recent gains. The "Magnificent Seven" tech stocks have mixed performance, with Apple and Tesla notably underperforming. The market is entering a historically strong July–August window, buoyed by trade optimism. U.S.–China relations show signs of improvement, including mutual resource access. Buy Now, Pay Later services are beginning to impact credit scores and consumer financial stability. Over 2.3 million households are delinquent on mortgage payments, with foreclosures up 34%. Renters face growing pressure, with 21% behind on payments and eviction filings surging. Mounting debt burdens are fueling disillusionment among younger Americans, increasing support for socialism. Inflation has cooled from 9% in 2022 to 2.4% in April 2025. Despite challenges, the U.S. is still viewed as one of the best places to live. For more information, visit the show notes at https://moneytreepodcast.com/end-of-quarter-performance-725  Today's Panelists: Kirk Chisholm | Innovative Wealth Douglas Heagren | ProCollege Planners Follow on Facebook: https://www.facebook.com/moneytreepodcast Follow LinkedIn: https://www.linkedin.com/showcase/money-tree-investing-podcast Follow on Twitter/X: https://x.com/MTIPodcast  

#89: My guest today is Alejandro Pérez Heinze who is a composer, Flamenco guitarist, audio engineer, Kontakt instrument producer, and audio educator based in Mexico. He has worked on a wide variety of projects including Kontakt instrument production on Kena: Bridge of Spirits, also working with Austin Wintory on projects such as Thai Cave Rescue, and composing on games such as Frogreign.   In this episode, we talk about Alejandro's extremely broad career path, starting off as an electric guitarist, switching over to Flamenco guitar, going to college for Biotech, and switching to audio production and engineering. We also talk about his unique skillset and how it landed him work in the game audio industry, and so much more.   Find Alejandro here: Website: https://www.alejandrophz.com/ LinkedIn: https://www.linkedin.com/in/alejandrophz/ Instagram: https://www.instagram.com/alejandro.phz/ SoundCloud: https://soundcloud.com/alejandrophz   Get info on The Game Industry Professional, my flagship course that teaches you how to make a great living in game audio here: bit.ly/gameindustrypro

Synopsis: Longevity isn't just about living longer—it's about living better. In this insightful episode of Biotech 2050, host Alok Tayi sits down with Sergey Jakimov, Founding Partner at LongeVC, to unpack what it really takes to invest in the future of healthspan. Blending his experience as a medtech entrepreneur, rare disease patient, and venture capitalist, Sergey shares why LongeVC focuses on practical, science-backed longevity solutions rather than hype-driven moonshots. He explains why aging isn't a disease, how diagnostics differ from therapeutics in venture ROI, and what makes AI drug discovery a pivotal unlock in modern biotech. The conversation also explores the rise of pet longevity, the role of lifestyle in aging, and how LongeVC grew from a €20M experiment to a high-performing fund now raising $250M for Fund Two—all with zero write-offs. For founders, funders, and anyone curious about the intersection of biotech, aging, and real-world outcomes, this episode offers an honest, no-fluff look at building the future of longevity—one evidence-based investment at a time. Biography: Sergey Jakimov is a founding partner of LongeVC, a venture capital fund supporting early-stage biotech and longevity-focused founders that are changing the world. He is a serial entrepreneur, having co-founded 3 deep-tech ventures and raised more than $40 million in venture funding for his own ventures and as an entrepreneur in residence. He has worked with several other early-stage companies in the therapeutics space on fundraising, IP protection, and clinical trial strategies, focusing on early treatments in cardiovascular, oncology, and neurodegenerative spaces. He is also a visiting lecturer to several universities on venture capital and intellectual property rights, and he co-authored a master's program in Technology Law for the Riga Graduate School of Law. Since 2018, he has co-founded medical tech startup Longenesis, a cutting-edge company that unlocks the hidden value of biomedical data and accelerates novel drug treatment & discovery. In 2020 he co-founded LongeVC, and in 2021, he co-founded the Longevity Science Foundation - a non-profit organization advancing the field of human longevity by funding research and development of medical technologies to extend the healthy human lifespan. He holds a BSc in International Affairs from Rīga Stradiņš University and two MScs in Political Science and Government and Law and Finance from Central European University and Riga Graduate School of Law, respectively. He was named Forbes Latvia 30 Under 30 in technology and healthcare in 2020.

In this episode of Let's Combinate, Archana shares her insights on the critical factors involved in designing clinical trials, from phase one safety profiling to pivotal phase three trials. She also discusses the importance of patient diversity, the ethical considerations in clinical research, and the future of clinical trials, including decentralized trials and the use of advanced technologies. The conversation highlights the intricate balance between maintaining rigorous scientific standards and adapting to new methodologies to enhance patient recruitment and data integrity. Time Stamps: 00:00 Welcome and Introduction 00:28 Understanding Clinical Trial Design 00:58 Phases of Clinical Trials 02:27 Oncology Trials and Patient Pathways 05:00 Protocol Design and Regulatory Considerations 08:40 Patient Preferences and Vendor Selection 18:53 Types of Clinical Trials 23:01 Understanding BA and BE Studies 24:39 Clinical Coordination of BA/BE Studies 25:15 Infrastructure and Emergency Management in Clinical Trials 26:19 Addressing Mistrust in Clinical Trials 29:54 Ensuring Diversity in Clinical Trials 32:41 The Rise of Decentralized Clinical Trials 39:06 Challenges and Solutions in Decentralized Trials 42:49 Technology and Regulation in Clinical Trials 47:28 Final Thoughts and Contact InformationArchana Sah is a Clinical development thought leader with extensive (30 years) experience and passion for developing medicines for patients having led and contributed to 15 FDA/EMEA drug approvals including Tecentriq® in multiple indications and combinations, Alecensa®, Polivy®, Hemlibra®, Gazyva®, Pixuvri®. She has held various global positions within Biotech, Big pharma, CRO including Genentech/Roche, Bayer Oncology, Johnson & Johnson, ICON, and two Oncology biotech start up companies. She has also worked in healthcare technology as the Senior Vice President of Digital and Decentralized Solutions at Medable Inc. She is now an independent strategy consultant and Board Advisor and provides strategic advisory services to pharma, biotechs, digital healthtech software companies, venture firms in clinical development and operations as well as on leveraging innovative patient centered digital health technologies in a fit for purpose approach to improve diversity, access and efficiencies within the healthcare ecosystem. She has been honored as Top20 women in immuno oncology drug development and featured in PharmaFEATURES on Oncology drug development and Digital Health technology.She has routinely led several industry collaboration consortiums. She is the co-founding chair and member of Society for Clinical Research Sites Oncology Board and chaired the Annual Oncology Summits. She is a current Mentor for the CancerX Moonshot program dedicated to revolutionizing advancements in cancer care, clinical trials, patient support, biotech & pharma and drive integration of digital tools in oncology. She serves on the Leadership Council for Decentralized Trials and Research Alliance(DTRA) and as their Evidence/Publications Librarian. She also serves as an Advisor to American Cancer Society Cancer Action Network (ACS CAN) and is a reviewer for the international Journal of the American Cancer Society "Cancer". Invited advisor and keynote/speaker at several industry conferences.Contact: archana.sah@aspharmaadvisors.comSubhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations, and R&D, he has worked in large Medical Device and Pharma organizations to support the development and launch of hardware devices, disposable devices, and combination products for vaccines, generics, and biologics.Subhi currently serves as the International Committee Chair for the Combination Products Coalition (CPC), is a member of ASTM Committee E55, and has served on AAMI's Combination Products Committee.

Bridging the gap between academia and industry isn't easy—but it's essential for innovation. In this episode, hosts Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, explore how biotech startups and academic institutions can break down silos and build stronger partnerships. From shared resources and mutual funding opportunities to culture shifts and advisory support, they reveal how deeper engagement between innovation hubs and industry players can lead to better science, better business, and better outcomes. In this episode, you'll learn: Why understanding each other's goals and processes is key to successful startup–university collaborations. How universities can help startups find funding, credibility, and critical talent—and what startups offer in return. Actionable tips for building long-term, win-win partnerships that drive innovation forward. Whether you're spinning out of a lab or investing in university research, this episode will give you new strategies to connect and collaborate with purpose. Links: Connect with Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, and learn about Tulane Medicine Business Development, the School of Medicine, and the National Primate Research Center. Connect with Katie Acuff, JD, MBA, Lauren Jardell, and Ellen Palmintier, JD, RN. Tune in to our previous episode on Boards of Directors and Scientific Advisory Boards. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. And click here to apply for a startup pitch slot. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Beckley's psychedelic nasal spray, BPL-003, has successfully cleared Phase II trials for treatment-resistant depression, showing robust efficacy data. Analysts predict the asset could reach peak market sales of $1 billion. This paves the way for late-stage development and a proposed merger with atai life sciences. In other news, M&A activity saw a significant increase in June, with big pharmas like Eli Lilly, Sanofi, and Novartis making multiple deals. The FDA's decision to remove risk evaluation and mitigation strategies from approved CAR T cancer therapies has been well-received by the cell and gene therapy community. Additionally, Argenx has made a $1.5 billion acquisition of Unum Therapeutics' macrocyclic peptides, aimed at "undruggable" targets. Moderna, Merck, UroGen, and other companies received regulatory nods for various treatments in June. Evotec is hosting a webinar on preserving quality in the pharma industry amidst financial challenges on July 16. Job opportunities in the industry include positions at Biomarin Pharmaceutical Inc., Regeneron Pharmaceuticals, and AbbVie.

Episode Description:If you've ever wondered what happens when a Bronx-born pediatric nurse with stage 4 colon cancer survives, raises a kid, becomes a policy shark, and fights like hell for the ignored, meet Vanessa Ghigliotty. She's not inspirational. She's a bulldozer. We go way back—like pre-Stupid Cancer back—when there was no “young adult cancer movement,” just a handful of pissed-off survivors building something out of nothing. This episode is personal. Vanessa and I built the plane while flying it. She fought to be heard, showed up in chemo dragging her kid to IEP meetings, and never stopped screaming for the rest of us to get what we needed. We talk war stories, progress, side-eyeing advocacy fads, TikTok activism, gatekeeping, policy wins, and why being loud is still necessary. And yeah—she's a damn good mom. Probably a better one than you. You'll laugh. You'll cry. You'll want to scream into a pillow. Come for the nostalgia. Stay for the righteous anger and iced coffee.RELATED LINKSVanessa on LinkedInColorectal Cancer Alliance: Vanessa's StoryZenOnco Interview with VanessaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ever feel like you're drowning in an ocean of constantly shifting regulatory guidelines? The world of biotech is a whirlwind of evolving standards, making compliance not just a headache, but sometimes the stumbling block between life-changing therapies and the patients who need them. But what if artificial intelligence could turn regulatory chaos into your biggest competitive advantage?In this episode, David Brühlmann sits down with Abhijeet Satwekar, Innovation Manager at Merck KGaA's Global Analytical Development. Abhijeet shares how he's pioneering the use of generative AI, not as a hype machine, but as a practical, transformative tool for regulatory compliance in biotech. With over a decade navigating analytics, digitalization, and collaborative tech adoption at a major pharma leader, Abhijeet knows what it takes to connect industry stakeholders, harness new technologies, and turn business operations into streamlined, value-generating systems.Here are three reasons you won't want to miss this episode:Generative AI as a Compliance Powerhouse: Discover how AI is being harnessed to analyze, extract, and compare complex regulatory requirements across different countries, cutting through ambiguous language and shifting specifications - so you don't have to.Reducing Regulatory Bottlenecks: The days of manually reconciling guideline documents and updating baselines with every regulatory change are numbered. Learn how generative AI accelerates multi-guideline comparison, saving teams countless hours and reducing the risk of costly errors and delays.A Blueprint for Digital Transformation: Abhijeet reveals how Merck is moving from proof-of-concept to operational reality, building collaborative teams that bridge IT, analytics, regulatory, and quality to bring valuable digital tools into daily practice.Curious if your team could automate away regulatory headaches? Listen in and get inspired to tackle your toughest compliance challenges - before your competitors do.Connect with Abhijeet Satwekar:LinkedIn: https://www.linkedin.com/in/abhijeetsatwekarNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing development: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotechSupport the show

What if a mouse could help shape the future of cancer treatment? In this episode of Sounds of Science, host Mary Parker speaks with Julia Schüler, DVM, PhD, Research Director and Therapeutic Area Lead for Oncology at Charles River. Julia shares how patient-derived xenograft (PDX) models—often described as “avatars” of human tumors—are transforming preclinical oncology research. From preserving tumor heterogeneity to improving translational relevance, PDX models are accelerating the discovery of more effective, personalized therapies. Tune in as we explore how these advanced models are driving innovation across the drug development pipeline—from target discovery to clinical trial design.Show NotesPDX Tumor Organoids : A New Tool in Drug Discovery Testing Realm Organoids: Some Assembly Required Patient-Derived Xenografts- PDX Models 3D Tumor Models In Vitro PDX Assays 

In this week's MBA Admissions podcast we began by discussing some of the recent activity on LiveWire, which is now becoming quieter as we move into the summer season. We then continued our discussion on the recent U.S. Government decisions as they pertain to international MBA students; Harvard appears to have won a recent decision in their fight with the U.S. Government in terms of being able to enroll international students.. Graham highlighted Clear Admit's summer series of webinars, which focuses on top MBA programs' admissions essays, which will be attended by more than 20 of the top MBA programs. The first event in the series includes Berkeley / Haas, Cornell / Johnson, Dartmouth / Tuck, Duke / Fuqua and UPenn / Wharton. Signups are here: https://bit.ly/mbaessay0725. Graham then noted two admissions tips; the first focuses on the importance of post MBA career goals, the second, part of Clear Admit's “Myth Busters” series, discusses the differences between targeting Round 1 and Round 2.. We continue our series of Adcom Q&As, which is a yearly series where we interview the admissions leaders at all the top MBA programs; this week we have Q&As from NYU / Stern and Georgetown / McDonough.. Finally, Graham highlighted a Real Humans alumni spotlight focusing on an alum from IESE working at PwC.. For this week, for the candidate profile review portion of the show, Alex selected three ApplyWire entries:. This week's first MBA admissions candidate has a 329 GRE score and a 3.4 GPA. They are working in the biotech sector, and plan to remain in that sector, post MBA. They want to do investment banking in the short term.. This week's second MBA candidate has a 3.86 GPA but has not taken the GMAT or GRE yet. They are also focused on the health care sector.. The final MBA candidate is from South Korea and has 10 years of experience in the tech sector, focusing on AI and robotics. They have a 685 GMAT score. This episode was recorded in Kansas City, Missouri and Cornwall, England. It was produced and engineered by the fabulous Dennis Crowley in Philadelphia, USA. Thanks to all of you who've been joining us and please remember to rate and review this show wherever you listen!

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York State's life sciences ecosystem while reflecting on her journey from Capitol Hill to biotech advocacy. Her experiences in politics, law, and biopharma government affairs uniquely positions her to navigate complex policy challenges while creating opportunities for biotech upstarts across New York and beyond. Jennifer also highlights key programs, capabilities, and funding on offer to early-stage biotech companies.  This episode of the Business of Biotech is brought to you by Ecolab Life Sciences. Learn more at https://www.ecolab.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

With growing FDA bottlenecks and regulatory changes, this episode explores how biotechs are looking beyond borders by rethinking trials, embracing real-world data, and finding new global pathways to bring therapies to life. Small Biotechs, Big Decisions is a limited podcast series exploring the challenges and opportunities facing emerging biotech companies, hosted by Daniel Chancellor, VP of Thought Leadership at Norstella, and Claire Riches, VP of Clinical Solutions at Citeline, a leading provider of life sciences data and insights. View the video series and find out more information here: https://www.citeline.com/biotech

Top officials gave updated damage assessments on the Trump administration's historic bunker bust of Iran's nuclear program. On Thursday, both the President and U.S. Defense Secretary Hegseth pushed back on media reports downplaying the efficacy of the strikes, emphasizing this was a "highly successful mission." FOX News Sunday anchor Shannon Bream joins to discuss the latest updates on Iran's nuclear capabilities, New York's Mayoral Democratic primary, and a Supreme Court ruling on funding to Planned Parenthood. Malaria kills around 600,000 people each year according to the World Health Organization, with mosquitoes largely responsible for spreading this deadly disease. Futurist Jamie Meltz, author of “Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives,” joins the podcast to explore the scientific possibility of editing mosquitoes' DNA in order to eliminate or genetically modify the entire species, while warning of the ethical and ecological risks when altering complex natural systems. Don't miss the good news with Tonya J. Powers. Plus, commentary by Brian Kilmeade, Host of One Nation with Brian Kilmeade and The Brian Kilmeade Show. Photo Credit: AP Learn more about your ad choices. Visit podcastchoices.com/adchoices

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.